Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritis.
Journal
Advances in rheumatology (London, England)
ISSN: 2523-3106
Titre abrégé: Adv Rheumatol
Pays: England
ID NLM: 101734172
Informations de publication
Date de publication:
27 05 2022
27 05 2022
Historique:
received:
28
05
2021
accepted:
15
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
To assess the ability of monoclonal antibodies (mAbs) specific for fibronectin extra-domain A (FnEDA) to target diseased tissues of mouse collagen induced arthritis (mCIA) models. To explore the parameters of the targeting exhibited by anti-FnEDA mAbs including timing and location. Targeting capabilities of anti-FnEDA mAbs were demonstrated by biodistribution study where i.v. injected antibodies were detected by conjugated near-infrared (NIR) fluorophore, Anti-FnEDA mAbs show specific targeting to diseased paws of mCIA animal. The targeting was focused on inflamed synovium which is consistent with FnEDA expression profile in both mCIA and human RA tissues. Anti-FnEDA mAbs accumulated in diseased tissue at pharmacologically relevant concentrations, the targeting was sustained for up to 14 days and FnEDA was able to support targeting of multiple doses of anti-FnEDA mAbs given 5 days apart. FnEDA is specifically upregulated in the inflamed tissues of mCIA. Antibodies specific for FnEDA can be useful as molecular delivery vehicles for disease specific targeting of payloads to inflamed joint tissue.
Identifiants
pubmed: 35624488
doi: 10.1186/s42358-022-00247-2
pii: 10.1186/s42358-022-00247-2
doi:
Substances chimiques
Antibodies, Monoclonal
0
Epitopes
0
Fibronectins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Informations de copyright
© 2022. The Author(s).
Références
Bahrami B, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64–83.
doi: 10.1016/j.imlet.2017.07.015
Trinh TL, et al. A synthetic aptamer-drug adduct for targeted liver cancer therapy. PLoS ONE. 2015;10(11): e0136673.
doi: 10.1371/journal.pone.0136673
Dolman ME, et al. Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev. 2010;62(14):1344–57.
doi: 10.1016/j.addr.2010.07.011
Liu Q, et al. Targeted drug delivery to melanoma. Adv Drug Deliv Rev. 2018;127:208–21.
doi: 10.1016/j.addr.2017.09.016
Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010;25(2):79–87.
doi: 10.5001/omj.2010.24
McGaraughty S, et al. Targeting anti-TGF-beta therapy to fibrotic kidneys with a dual specificity antibody approach. J Am Soc Nephrol. 2017;28(12):3616–26.
doi: 10.1681/ASN.2017010013
Schmid AS, et al. Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis. Rheumatology (Oxford). 2018;57(4):748–55.
doi: 10.1093/rheumatology/kex447
Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197–207.
doi: 10.1038/s41584-019-0188-8
Zollinger AJ, Smith ML. Fibronectin, the extracellular glue. Matrix Biol. 2017;60–61:27–37.
doi: 10.1016/j.matbio.2016.07.011
Romberger DJ. Fibronectin. Int J Biochem Cell Biol. 1997;29(7):939–43.
doi: 10.1016/S1357-2725(96)00172-0
Kriegsmann J, et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int. 2004;24(1):25–33.
doi: 10.1007/s00296-003-0316-1
Hino K, et al. EDA-containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells. Arthritis Rheum. 1995;38(5):678–83.
doi: 10.1002/art.1780380516
Schwager K, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
doi: 10.1186/ar2814
Rybak JN, et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 2007;67(22):10948–57.
doi: 10.1158/0008-5472.CAN-07-1436
Borsi L, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102(1):75–85.
doi: 10.1002/ijc.10662
Bruijnen STG, et al. F8-IL10: a new potential antirheumatic drug evaluated by a PET-guided translational approach. Mol Pharm. 2019;16(1):273–81.
doi: 10.1021/acs.molpharmaceut.8b00982
Przybysz M, Borysewicz K, Katnik-Prastowska I. Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin. Rheumatol Int. 2009;29(12):1397–401.
doi: 10.1007/s00296-009-0866-y
Hemmerle T, Doll F, Neri D. Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci U S A. 2014;111(33):12008–12.
doi: 10.1073/pnas.1402783111
Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today. 2012;17(11–12):583–90.
doi: 10.1016/j.drudis.2012.01.007
Kragstrup TW, et al. Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis. BMC Rheumatol. 2019;3:46.
doi: 10.1186/s41927-019-0093-4